|
#197
14.02.2010, 23:32
|
|||
|
|||
|
Äîáðûé âå÷åð Îëüãà!
Öèòàòà:
×òî/êàê äîëæíî èçìåíèòüñÿ çà èíòåðâàë âðåìåíè >48 ÷àñîâ? 
|
|
#198
15.02.2010, 00:23
|
|||
|
|||
|
Äëÿ ïðèâëå÷åíèÿ èíòåðåñà ê ðàçäåëó, áóäó ïîäáðàñûâàòü ñþäà àôîðèçìû è öèòàòû...
“When doctors, statisticians and scientists become ill, they ask "Who is the best doctor for this problem?" and not "Which multi-centre controlled trial would be best for me?" (--E.J. Freireich from the MD Anderson Hospital). “Any study that reports a certain number of consecutive cases without a complication (death) actually means that number of cases plus two were performed with two complications (deaths) ;the first and last.” (--Michael Hoffman).
|
|
#199
15.02.2010, 00:25
|
|||
|
|||
|
Äîáðûé âå÷åð, Àëåêñàíäð.
Êàê çâó÷èò ïðåäëîæåíèå öåëèêîì? Measurable èìååò åùå çíà÷åíèå "óìåðåííûé; çàìåòíûé" Àíãë-àíãë ñëîâàðü Collins äàåò ñëåäóþùóþ òðàêòîâêó ýòîìó ñëîâó: able to be measured; perceptible or significant
|
|
#200
15.02.2010, 00:32
|
|||
|
|||
|
Öèòàòà:
relative contraindications include recent central nervous system bleeds; intracranial or spinal lesions at high risk for bleeding; active bleeding (morethan two units transfused in 24 h); chronic, clinically significant measurable bleeding (>48 h); thrombocytopenia (<50 000/mm3);
|
|
#201
15.02.2010, 01:32
|
|||
|
|||
|
Ëàáîðàòîðíî ãåìîãëîáèí, ãåìàòîêðèò è ò.ä.
×åñòíî ãîâîðÿ, íå ïîíèìàþ, ÷òî àâòîðû ïîäðàçóìåâàëè ïîä "êëèíè÷åñêè âàæíîå èçìåðèìîå êðîâîòå÷åíèå", ïðèçíàêè øîêà èëè ÄÂÑ-ñèíäðîìà, èëè ÷òî òî äðóãîå...
|
|
#203
15.02.2010, 17:58
|
|||
|
|||
|
Ïîêà æäåì "òÿæåëîé àðòèëëåðèè" ïî èçìåðåíèþ õðîíè÷åñêîãî êðîâîòå÷åíèÿ, åù¸ îäèí ãåìàòîëîãè÷åñêè îðèåíòèðîâàíûé êâèç :-)
to discuss major areas of concern, identify the therapeutic issues and develop recommendations and review-associated evidence for the management of myeloma bone disease. Íó è äëÿ "ïîäíÿòèÿ" ïîñòà.... “Any study that reports a certain number of consecutive cases without a complication (death) actually means that number of cases plus two were performed with two complications (deaths) ;the first and last.” (--Michael Hoffman) “The good thing about standard of care is that there are so many to choose from.”
|
|
#205
16.02.2010, 13:32
|
|||
|
|||
|
ß áû ïåðåâîäèë ñëåäóþùèì îáðàçîì:
chronic, clinically significant measurable bleeding (>48 h); õðîíè÷åñêîå (ïðîäîëæàþùååñÿ ñâûøå 48 ÷àñîâ) êëèíè÷åñêè çíà÷èìîå êðîâîòå÷åíèå, îïðåäåëÿåìîå âèçóàëüíî è/èëè ëàáîðàòîðíî to discuss major areas of concern, identify the therapeutic issues and develop recommendations and review-associated evidence for the management of ...[ñ öåëüþ] îáñóäèòü îñíîâíûå íåðåøåííûå ïðîáëåìû, îïðåäåëèòü òåðàïåâòè÷åñêèå ïîäõîäû è ðàçðàáîòàòü ðåêîìåíäàöèè ñ âûäåëåíèåì ãðàäàöèé [ñèëû] ðåêîìåíäàöèé íà îñíîâå [ïðîâåäåííîãî] ñèñòåìàòè÷åñêîãî îáçîðà äëÿ ëå÷åíèÿ... Íî ýòî òîëüêî ìîå ÈÌÕÎ  .
|
|
#207
24.02.2010, 22:40
|
|||
|
|||
|
Öèòàòà:
È íå èìååò çíà÷åíèÿ ñ ïðèäàòêàìè èëè áåç. Èõ ïèøèòå îòäåëüíî (äðóãîé îðãàí). À "ñàêòîñàëüïèíêñ", íå óâåðåí, ÷òî â àíãëèéñêîì åñòü àíàëîãè÷íûé òåðìèí. ×åì Âàñ íå óñòðàèâàåò chronical salpyngitis with obstruction
|
|
#208
26.02.2010, 15:08
|
||||
|
||||
|
Äîðîãèå êîëëåãè, ïîäñêàæèòå ïîæàëóéñòà ïåðåâîä äëÿ lifetime analytic horizon è quality-adjusted life years
Âðîäå ïåðåâåëà êàê "ïîæèçíåííûé àíàëèòè÷åñêèé ãîðèçîíò" è "ãîäû æèçíè ñ ïîïðàâêîé íà êà÷åñòâî æèçíè", íî çàñîìíåâàëàñü - âîçìîæíî, åñòü äðóãîé îáùåïðèíÿòûé âàðèàíò?
|
|
#209
26.02.2010, 18:10
|
|||
|
|||
|
Öèòàòà:
|
|
#210
26.02.2010, 21:42
|
|||
|
|||
|
Öèòàòà:
Íó, ìíå òàê êàæåòñÿ (ñ) quality-adjusted life years îäíîçíà÷íîãî ïåðåâîäà íå âñòðå÷àë, áûëî è "êîëè÷åñòâî ëåò æèçíè ñ ñîõðàíåííûì/ïðèåìëåìûì êà÷åñòâîì" À âîò èç ìóëüòèòðàíà quality adjusted life year ìåä. ãîä æèçíè ñ ïîïðàâêîé íà å¸ êà÷åñòâî (Dimpassy) Quality adjusted life year ìåä. ãîä æèçíè, ïðîæèòûé êà÷åñòâåííî (ñîêð. QALY alf77); ïðèâåä¸ííûé ïåðåñ÷èòàííûé ïî êà÷åñòâó ãîä æèçíè (alf77); ñêîððåêòèðîâàííûé íà êà÷åñòâî æèçíè ãîä (alf77); ñîõðàí¸ííûé ãîä æèçíè ñ ó÷¸òîì å¸ êà÷åñòâà (Vosoni)
|
Ëèíåéíûé âèä
